Loading…
Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate...
Saved in:
Published in: | Cost effectiveness and resource allocation 2011-04, Vol.9 (1), p.4-4 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-b4914-2c8df97b9f91d3c9fc3adaa74f7cbfaa6d3cad3381d2e0d2cb63c89c8b0f1d633 |
---|---|
cites | |
container_end_page | 4 |
container_issue | 1 |
container_start_page | 4 |
container_title | Cost effectiveness and resource allocation |
container_volume | 9 |
creator | Perman, Gastón Rossi, Emiliano Waisman, Gabriel D Agüero, Cristina González, Claudio D Pallordet, Carlos L Figar, Silvana González Bernaldo de Quirós, Fernán Canning, Joann Soriano, Enrique R |
description | Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer.
We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.
The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.
Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.
The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice. |
doi_str_mv | 10.1186/1478-7547-9-4 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5fa6c9085c734a13ae5652a3fe0aa624</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A254993278</galeid><doaj_id>oai_doaj_org_article_5fa6c9085c734a13ae5652a3fe0aa624</doaj_id><sourcerecordid>A254993278</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4914-2c8df97b9f91d3c9fc3adaa74f7cbfaa6d3cad3381d2e0d2cb63c89c8b0f1d633</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEoqVw5IoiceCUEn8kjjmgVisKlYq4wNma2OOtS2IHO7vS_nsctl11BcgH2zPvPJ7xTFG8JvU5IV37nnDRVaLhopIVf1KcHu5PH51Pihcp3dU1ZbTunhcnlPC2bWVzWvSrkOYKrUU9uy16TKkMtoTydjdhnNEnF3w5goc1jujncophHWEcsXS-BF_iYDAOu3IK02aAOas_5OivEH-GbTkGg8PL4pmFIeGr-_2s-HH16fvqS3Xz7fP16vKm6rkkvKK6M1aKXlpJDNPSagYGQHArdG8B2mwEw1hHDMXaUN23THdSd31tiWkZOyuu91wT4E5N0Y0QdyqAU38MIa4VxNnpAVVjodWy7hotGAfCAJu2ocAs1vkhyjPr4541bfoRjc6VRxiOoMce727VOmwVqztOmiYDLvaA3oX_AI49Ooxq6Zda-qWkWnJ4d59DDL82mGY1uqRxGMBj2CTVCcFrQZsuK9_ulWvIxTlvQ0bqRa0uacOlZFQsqvN_qPIyODodPFqX7UcB1T5Ax5BSRHtIn9RqGb6_En7z-NMO6odpY78BpaTXWQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>877407258</pqid></control><display><type>article</type><title>Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model</title><source>Open Access: PubMed Central</source><source>ABI/INFORM Global (ProQuest)</source><source>ProQuest - Publicly Available Content Database</source><creator>Perman, Gastón ; Rossi, Emiliano ; Waisman, Gabriel D ; Agüero, Cristina ; González, Claudio D ; Pallordet, Carlos L ; Figar, Silvana ; González Bernaldo de Quirós, Fernán ; Canning, Joann ; Soriano, Enrique R</creator><creatorcontrib>Perman, Gastón ; Rossi, Emiliano ; Waisman, Gabriel D ; Agüero, Cristina ; González, Claudio D ; Pallordet, Carlos L ; Figar, Silvana ; González Bernaldo de Quirós, Fernán ; Canning, Joann ; Soriano, Enrique R</creatorcontrib><description>Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer.
We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.
The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.
Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.
The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.</description><identifier>ISSN: 1478-7547</identifier><identifier>EISSN: 1478-7547</identifier><identifier>DOI: 10.1186/1478-7547-9-4</identifier><identifier>PMID: 21466695</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged patients ; Care and treatment ; Demographic aspects ; Economic aspects ; Hypertension ; Markov processes</subject><ispartof>Cost effectiveness and resource allocation, 2011-04, Vol.9 (1), p.4-4</ispartof><rights>COPYRIGHT 2011 BioMed Central Ltd.</rights><rights>Copyright ©2011 Perman et al; licensee BioMed Central Ltd. 2011 Perman et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4914-2c8df97b9f91d3c9fc3adaa74f7cbfaa6d3cad3381d2e0d2cb63c89c8b0f1d633</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084155/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084155/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,36060,37012,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21466695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perman, Gastón</creatorcontrib><creatorcontrib>Rossi, Emiliano</creatorcontrib><creatorcontrib>Waisman, Gabriel D</creatorcontrib><creatorcontrib>Agüero, Cristina</creatorcontrib><creatorcontrib>González, Claudio D</creatorcontrib><creatorcontrib>Pallordet, Carlos L</creatorcontrib><creatorcontrib>Figar, Silvana</creatorcontrib><creatorcontrib>González Bernaldo de Quirós, Fernán</creatorcontrib><creatorcontrib>Canning, Joann</creatorcontrib><creatorcontrib>Soriano, Enrique R</creatorcontrib><title>Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model</title><title>Cost effectiveness and resource allocation</title><addtitle>Cost Eff Resour Alloc</addtitle><description>Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer.
We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.
The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.
Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.
The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.</description><subject>Aged patients</subject><subject>Care and treatment</subject><subject>Demographic aspects</subject><subject>Economic aspects</subject><subject>Hypertension</subject><subject>Markov processes</subject><issn>1478-7547</issn><issn>1478-7547</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kk1v1DAQhiMEoqVw5IoiceCUEn8kjjmgVisKlYq4wNma2OOtS2IHO7vS_nsctl11BcgH2zPvPJ7xTFG8JvU5IV37nnDRVaLhopIVf1KcHu5PH51Pihcp3dU1ZbTunhcnlPC2bWVzWvSrkOYKrUU9uy16TKkMtoTydjdhnNEnF3w5goc1jujncophHWEcsXS-BF_iYDAOu3IK02aAOas_5OivEH-GbTkGg8PL4pmFIeGr-_2s-HH16fvqS3Xz7fP16vKm6rkkvKK6M1aKXlpJDNPSagYGQHArdG8B2mwEw1hHDMXaUN23THdSd31tiWkZOyuu91wT4E5N0Y0QdyqAU38MIa4VxNnpAVVjodWy7hotGAfCAJu2ocAs1vkhyjPr4541bfoRjc6VRxiOoMce727VOmwVqztOmiYDLvaA3oX_AI49Ooxq6Zda-qWkWnJ4d59DDL82mGY1uqRxGMBj2CTVCcFrQZsuK9_ulWvIxTlvQ0bqRa0uacOlZFQsqvN_qPIyODodPFqX7UcB1T5Ax5BSRHtIn9RqGb6_En7z-NMO6odpY78BpaTXWQ</recordid><startdate>20110405</startdate><enddate>20110405</enddate><creator>Perman, Gastón</creator><creator>Rossi, Emiliano</creator><creator>Waisman, Gabriel D</creator><creator>Agüero, Cristina</creator><creator>González, Claudio D</creator><creator>Pallordet, Carlos L</creator><creator>Figar, Silvana</creator><creator>González Bernaldo de Quirós, Fernán</creator><creator>Canning, Joann</creator><creator>Soriano, Enrique R</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20110405</creationdate><title>Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model</title><author>Perman, Gastón ; Rossi, Emiliano ; Waisman, Gabriel D ; Agüero, Cristina ; González, Claudio D ; Pallordet, Carlos L ; Figar, Silvana ; González Bernaldo de Quirós, Fernán ; Canning, Joann ; Soriano, Enrique R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4914-2c8df97b9f91d3c9fc3adaa74f7cbfaa6d3cad3381d2e0d2cb63c89c8b0f1d633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged patients</topic><topic>Care and treatment</topic><topic>Demographic aspects</topic><topic>Economic aspects</topic><topic>Hypertension</topic><topic>Markov processes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perman, Gastón</creatorcontrib><creatorcontrib>Rossi, Emiliano</creatorcontrib><creatorcontrib>Waisman, Gabriel D</creatorcontrib><creatorcontrib>Agüero, Cristina</creatorcontrib><creatorcontrib>González, Claudio D</creatorcontrib><creatorcontrib>Pallordet, Carlos L</creatorcontrib><creatorcontrib>Figar, Silvana</creatorcontrib><creatorcontrib>González Bernaldo de Quirós, Fernán</creatorcontrib><creatorcontrib>Canning, Joann</creatorcontrib><creatorcontrib>Soriano, Enrique R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Cost effectiveness and resource allocation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perman, Gastón</au><au>Rossi, Emiliano</au><au>Waisman, Gabriel D</au><au>Agüero, Cristina</au><au>González, Claudio D</au><au>Pallordet, Carlos L</au><au>Figar, Silvana</au><au>González Bernaldo de Quirós, Fernán</au><au>Canning, Joann</au><au>Soriano, Enrique R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model</atitle><jtitle>Cost effectiveness and resource allocation</jtitle><addtitle>Cost Eff Resour Alloc</addtitle><date>2011-04-05</date><risdate>2011</risdate><volume>9</volume><issue>1</issue><spage>4</spage><epage>4</epage><pages>4-4</pages><issn>1478-7547</issn><eissn>1478-7547</eissn><abstract>Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer.
We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.
The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.
Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.
The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21466695</pmid><doi>10.1186/1478-7547-9-4</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1478-7547 |
ispartof | Cost effectiveness and resource allocation, 2011-04, Vol.9 (1), p.4-4 |
issn | 1478-7547 1478-7547 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_5fa6c9085c734a13ae5652a3fe0aa624 |
source | Open Access: PubMed Central; ABI/INFORM Global (ProQuest); ProQuest - Publicly Available Content Database |
subjects | Aged patients Care and treatment Demographic aspects Economic aspects Hypertension Markov processes |
title | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A39%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20a%20hypertension%20management%20programme%20in%20an%20elderly%20population:%20a%20Markov%20model&rft.jtitle=Cost%20effectiveness%20and%20resource%20allocation&rft.au=Perman,%20Gast%C3%B3n&rft.date=2011-04-05&rft.volume=9&rft.issue=1&rft.spage=4&rft.epage=4&rft.pages=4-4&rft.issn=1478-7547&rft.eissn=1478-7547&rft_id=info:doi/10.1186/1478-7547-9-4&rft_dat=%3Cgale_doaj_%3EA254993278%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b4914-2c8df97b9f91d3c9fc3adaa74f7cbfaa6d3cad3381d2e0d2cb63c89c8b0f1d633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=877407258&rft_id=info:pmid/21466695&rft_galeid=A254993278&rfr_iscdi=true |